NEW HYBRID STRUCTURES BASED ON MEMANTHINE AND EDARAVONE MOLECULES

V. V. Grigoriev; Григорьев В. В.; A. Yu. Aksinenko; Шевцова Е. Ф.; E. F. Shevtsova; Аксиненко А. Ю.; T. V. Goreva; Веселов И. М.; I. M. Veselov; Горева Т. В.; A. V. Gabrelyan; Габрельян А. В.; S. O. Bachurin; Бачурин С. О.

doi:10.31857/S2686738923600413

NEW HYBRID STRUCTURES BASED ON MEMANTHINE AND EDARAVONE MOLECULES

Авторлар: Grigoriev V.¹, Aksinenko A.¹, Shevtsova E.¹, Goreva T.¹, Veselov I.¹, Gabrelyan A.¹, Bachurin S.¹
Мекемелер:
1. Institute of Physiologically Active Substances, Federal State Budgetary Institution of Science, Federal Research Center for Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences
Шығарылым: Том 512, № 1 (2023)
Беттер: 466-469
Бөлім: Articles
URL: https://journals.rcsi.science/2686-7389/article/view/140857
DOI: https://doi.org/10.31857/S2686738923600413
EDN: https://elibrary.ru/PYWTWG
ID: 140857

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат
Рұқсат жабық

Рұқсат берілді
Рұқсат жабық

Тек жазылушылар үшін

Аннотация
Авторлар туралы
Әдебиет тізімі
Қосымша файлдар
Статистика

Аннотация

New hybrid structures based on memantine and edaravone molecules, in which the pyrazolone ring and adamantane fragments are linked by an alkyl linker, have been synthesized. It was found that in addition to the ability to block the intrachanal site of NMDA receptors, new hybrid compounds exhibit the property of blockers of the allosteric site of NMDA receptors, which is not inherent in memantine and edaravone preparations. The most active hit compound was determined, which, along with the properties of a two-site blocker of the NMDA receptor, exhibits a pronounced activity as an inhibitor of lipid peroxidation, similar to the drug edaravone.

Негізгі сөздер

amyotrophic lateral sclerosis, Alzheimer’s disease, memantine, edaravone, 1-aminoadamantanes, NMDA receptors, oxidative stress, lipid peroxidation

Әдебиет тізімі

P.V. Peplow, B. Martinez, T.A. Gennarelli, Eds. Neurodegenerative Diseases Biomarkers: Towards Translating Research to Clinical Practice. Springer US, 2021, 565 p.
Blasco H., Mavel S., Corcia P., Gordon P.H. // Curr Med Chem. 2014. V. 21. № 31. P. 3551–3375.
Wang R., Reddy P.H. // J Alzheimers Dis. 2017. V. 57. № 4. P. 1041–1048.
Ahmed H., Haider A., Ametamey S.M. // Expert Opin Ther Pat. 2020. V. 30. № 10. P. 743–767.
Tikhonova I.G., Baskin I.I., Palyulin V.V., Zefirov N.S., Bachurin S.O. // J. Med. Chem. 2002. V. 45. № 18. P. 3836–3843.
Lipton S.A. // Nat. Rev. Drug Discov. 2006. V. 5. № 2. P. 160–170.
Jiang J., Wang Y., Deng M. // Front Pharmacol. 2022. V. 28. № 13. 1054006.
Angelova P.R., Esteras N., Abramov A.Y. // Med Res Rev. 2021. V. 41. № 2. P. 770–784.
Jaiswal M.K. // Med Res Rev. 2019. V. 39. № 2. P. 733–748.
Savelieff M.G., Nam G., Kang J., et al. // Chem Rev. 2019. V. 119. № 2. P. 1221–1322.
Bachurin S.O., Makhaeva G.F., Shevtsova E.F., et al. // Molecules. 2021. V. 26. 5527.
Bachurin S.O., Shevtsova E.F., Makhaeva G.F., et al. // Int J Mol Sci. 2022. V. 23. № 22. 13925.
Аксиненко А.Ю., Горева Т.В., Епишина Т.А., Бачурин С.О. // Изв. АН. Сер. хим., 2022. № 8. С. 1794–1800.
Махаева Г.Ф., Шевцова Е.Ф., Болтнева Н.П., и др. // Доклады РАН, Биохимия, биофизика, 2019. Т. 484. № 1. С. 104–108. https://doi.org/10.7868/S0205-961448410104-108
Ugale V., Dhote A., Narwade R., et al. // CNS & Neurological Disorders – Drug Targets. 2021. V. 20. Iss. 9.